Beijing State Capital Leads $560M Series D Round in AI-Driven Drug Delivery Firm GenEdit Bio

Aug 04, 2025 18:42 CST Updated 18:42

METiS TechBio

AI-Driven Drug Formulation Developer

Today, METiS TechBio announced that it has recently completed$400 Million Series D Financing. This round of financing was led byBeijing Medical and Health Industry Investment FundAndDaxing District Industrial Investment FundCo-led.

The financing will accelerate the advancement of several strategic priorities for METiS TechBio, including platform automation upgrades, progress in the self-developed product pipeline, deepening international strategic cooperation, and the recruitment of top talents.

METiS TechBio was founded in 2020 as a biotechnology company driven by AI-powered nanomaterial innovation.Focus on Utilizing Targeted Drug Delivery and Discovery Technologies, helping living organisms overcome diseases and aging, and regain health and vitality.

The company was founded by a member of the National Academy of Engineering in the United States.Dr. Chen Hongminand MIT scientistsDr. Lai Caida、Dr. Wang WenshouCo-founded, successfully independently developed the AI nano-base large model and three core solutions: AiLNP (AI Nucleic Acid Delivery System Design Platform), AiRNA (AI mRNA Sequence Design Platform), AiTEM (AI Small Molecule Formulation Design Platform).

The company has achieved precise targeting and delivery capabilities of lipid nanoparticles (LNPs) to key tissues and cells such as the liver, lungs, muscles, and immune cells. It has made breakthrough progress in solving the challenges of multi-organ and multi-tissue targeted delivery, providing druggable opportunities for various diseases and offering possibilities for resisting aging at the organ level in living organisms.

METiS TechBio, the leading innovator in AI nanodelivery, held the OpenCGT platform inauguration and Series D financing release conference on August 1 at the Zhongguancun (Daxing) Cell Gene Therapy Industrial Park.

Beijing Medical and Health Industry Investment Fund (referred to as "Beijing Medical and Health Fund") is one of the eight industrial funds approved by the Beijing Municipal Government. It focuses on key industrial areas such as innovative drugs and innovative medical devices, as well as emerging industry fields like cell and gene therapy and digital healthcare, aiming to inject new and strong momentum into the development of new productive forces in Beijing.

Mr. Peng Ren, Chairman and General Manager of Shunxi Management Company, stated:"Medicine and health are key to Beijing's innovation-driven development and cultivation of new productive forces. With the recent introduction of Beijing's action plan to accelerate the innovative development of artificial intelligence + medicine and health, Beijing, with a forward-looking strategic vision, deeply integrates AI + medicine and health, empowers industrial upgrading through intelligent technology, leads high-quality development with an innovative ecosystem, and provides a Beijing solution for fostering new productive forces in the biopharmaceutical field."

Beijing has established a total scale20 billion yuanThe pharmaceuticals and health industry investment fund focuses on cutting-edge fields such as innovative drugs, innovative medical devices, cell and gene therapy, and digital healthcare. The METiS TechBio OpenCGT platform fills a critical gap in the industrial transformation of advanced formulations and delivery systems, helping Beijing become an international CGT industry innovation hub. We look forward to METiS TechBio setting a new benchmark for AI-driven drug discovery.

Li Ming, Party Secretary and Chairman of Beijing Daxing District Investment Group Co., Ltd., said:"As the new gateway to the capital, Daxing District has always been firmly committed to developing the biopharmaceuticals industry as the core track for high-quality development, making every effort to establish the China Medicine Valley brand. The landing of the OpenCGT platform empowered by METiS TechBio will not only accelerate the transformation of original innovative achievements but also attract top global talent, technology, and capital to gather in Daxing, further enhancing our international competitiveness in the CGT field."

Huang Hantao, Deputy General Manager of CICC Capital, said:"We are very grateful to the Beijing municipal government, various commissions and bureaus, Shunxi Management Company, and Daxing District for their solid support to METiS TechBio in terms of policies, funding, talent, and industrial space. We also highly recognize the significant progress METiS TechBio has made over the past two years. As an existing shareholder, CICC Capital will continue to empower METiS in multiple aspects such as R&D collaboration, talent acquisition, clinical development, and capital markets. We will stand by METiS in the long term as they lead the revolutionary wave of AI + drug delivery and advance China's drug delivery technology innovation, empowering breakthroughs in drug development for partners across China and even globally."

Dr. Cai-Da Lai, Co-founder and CEO of METiS TechBio, stated:"Thanks to the long-term trust and support from leaders at all levels in Beijing, investors, and industry partners for METiS TechBio. It is the mission of METiS TechBio to solve the nanodelivery challenges with AI innovation, and it is also our commitment to leaders and partners from all sectors. We will continue to advance the innovation process of our independent research and development, providing Chinese delivery solutions for the high-quality development of the CGT industry."

Cell and Gene Therapy (CGT)It is the main track of the third-generation drug innovation following small-molecule drugs and antibody drugs. In 2024, the Beijing Municipal Science & Technology Commission, Zhongguan Village Management Committee, and four other departments jointly released the "Three-Year Action Plan for Accelerating the Innovative Development of Cell and Gene Therapy Industry in Beijing," clearly stating that "by 2027, Beijing will cultivate more than 20 cutting-edge technologies in the CGT field and accelerate the formation of a cell and gene therapy industry cluster with international influence."

The unveiling ofMETiS TechBio OpenCGT Technology PlatformAimed at addressing the industry pain points of precise drug delivery, reducing development barriers and costs, incubating and empowering the R&D and clinical transformation of breakthrough CGT therapies, and assisting Beijing in building a "new engine" for the life and health industry.

—The End—

Recommended Reading